QC
AKBA icon

Quadrature Capital’s Akebia Therapeutics AKBA Stock Holding History

Quadrature Capital’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-89,261
Closed -$124K – 1562
2026
Q1 		$124K Buy
89,261
+72,700
+439% +$99.9K ﹤0.01% 1195
2025
Q4 		$26.7K Buy
16,561
+6,293
+61% +$13.2K ﹤0.01% 1200
2025
Q3 		$28.1K Sell
10,268
-71,676
-87% -$238K ﹤0.01% 981
2025
Q2 		$297K Buy
81,944
+54,691
+201% +$150K 0.01% 693
2025
Q1 		$52.1K Buy
+27,253
New +$55.6K ﹤0.01% 973

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Quadrature Capital's AKBA Position: Q2 2026 in Review

Quadrature Capital sold out of Akebia Therapeutics (AKBA) in Q2 2026, closing a stake of 89,261 shares — an estimated $124K sold.

Quadrature Capital first reported a position in AKBA in Q1 2025 and held it in 5 quarters. The position peaked at $297K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Quadrature Capital reported no remaining Akebia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrature Capital sold 89,261 Akebia Therapeutics shares in Q2 2026, an estimated $124K.
  • Quadrature Capital first reported a position in Akebia Therapeutics in Q1 2025 and held it in 5 quarters.
  • Quadrature Capital's Akebia Therapeutics position peaked at $297K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.